What question did this study set out to answer?

To assess whether adding boceprevir to standard peginterferon-ribavirin therapy improves sustained virologic response rates in previously untreated adults with chronic hepatitis C virus genotype 1 infection.

March 30, 2011New England Journal of MedicineOpen Access

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

View Full Paper

Ask AI

Bookmark

Authors

FPFred PoordadThe University of Texas Health Science Center at San Antonio JMJonathan McConeVernon College BBBruce R. BaconUniversity of Arkansas at Little Rock

Discussion

Member takes

Implication

Randomized double-blind trial reveals that adding boceprevir improves sustained virologic response in untreated HCV genotype 1 infection, indicating substantial clinical benefit over standard care.

Key Points

To assess whether adding boceprevir to standard peginterferon-ribavirin therapy improves sustained virologic response rates in previously untreated adults with chronic hepatitis C virus genotype 1 infection.
Double-blind randomized trial (NCT00705432) enrolling 1,097 previously untreated adults (938 nonblack and 159 black) with chronic HCV genotype 1 infection, analyzed separately by race.
All patients underwent a 4-week lead-in with peginterferon alfa-2b and ribavirin before assignment to 44 weeks of placebo plus standard therapy (group 1), response-guided boceprevir for 24 weeks with conditional standard therapy (group 2), or 44 weeks of boceprevir plus standard therapy (group 3).
Among nonblack patients, sustained virologic response was 40% (125/311) in group 1, compared to 67% (211/316; P<0.001) in group 2 and 68% (213/311; P<0.001) in group 3.
Among black patients, sustained virologic response was 23% (12/52) in group 1, compared to 42% (22/52; P=0.04) in group 2 and 53% (29/55; P=0.004) in group 3.
Anemia prompted dose reductions in 13% of controls versus 21% of boceprevir recipients, leading to treatment discontinuation in 1% and 2% of patients, respectively.

Cite This Study

Poordad et al. (2011) studied this question.

synapsesocial.com/papers/6a1558ff9b87f33fc69f78a9 https://doi.org/10.1056/nejmoa1010494

View Full Paper

Ask AI

Bookmark

Implication

Randomized double-blind trial reveals that adding boceprevir improves sustained virologic response in untreated HCV genotype 1 infection, indicating substantial clinical benefit over standard care.

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

Discussion

Member takes

Implication

Key Points

Cite This Study

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider